Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Opendoor Technologies Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $109.67 (market cap $12.58B), while Opendoor Technologies Inc trades at $2.31 (market cap $2.20B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 5.7× Opendoor Technologies Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Opendoor Technologies Inc for 33 Days on average.
| HALO | OPEN | |
|---|---|---|
Market Cap | $12.58B | $2.20B |
Volume | 2,179,278 | 35,582,488 |
Sector | Health | Real Estate |
52-Week High | $115.22 | $9.37 |
52-Week Low | $61.63 | $2.27 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $14.49B | $3.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Opendoor Technologies trades at $2.29, up 0.88% with a bearish technical outlook. The company shows concerning fundamentals with a -46.74% net income margin and -$1.3B net loss despite $4.37B revenue. Recent earnings misses and negative cash flow trends highlight operational challenges, though mortgage expansion to 35-40 states by end-2026 offers potential growth. Analyst consensus is mixed with 26.9% buy ratings but a $4.92 price target suggesting 115% upside from current levels.
The stock presents high-risk speculative potential with significant operational turnaround required. While valuation appears attractive at 0.62 P/S ratio, persistent losses and housing market sensitivity create substantial downside risk. The mortgage expansion initiative could drive recovery if execution improves, but investors face volatility from rate sensitivity and competitive pressures in the iBuyer space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
